Key result
Domperidone exposure was associated with a modestly increased risk of severe ventricular arrhythmia compared with non-use (adjusted IRR 1.342), though this risk was lower than that of itopride.
Why the study?
Cardiovascular safety of domperidone remains controversial due to inconsistent results and a lack of well-designed studies.
Does domperidone increase the risk of severe ventricular arrhythmia compared to non-use or other prokinetics in the general population?
Population
2,817 individuals diagnosed with severe VA and prescribed domperidone, mosapride, or itopride
Comparison
Domperidone exposure vs mosapride, itopride, or unexposed periods
Design
Population-based self-controlled case series analysis
Authors
Loading...
While domperidone is associated with a modestly increased risk of severe ventricular arrhythmia compared to non-use, it does not increase the risk further when compared to other commonly prescribed prokinetics like itopride.
Observational (n=2,817)
Does domperidone increase the risk of severe ventricular arrhythmia compared to non-use or other prokinetics in the general population?
Relative Risk: 1.342 (95% CI 1.096–1.642)
Absolute Event Rate: 14.4% vs 9.9%
While domperidone is associated with a modestly increased risk of severe ventricular arrhythmia compared to non-use, it does not increase the risk further when compared to other commonly prescribed prokinetics like itopride.
Song et al. (2020) conducted an observational in Severe ventricular arrhythmia (n=2,817). Domperidone vs. Non-use was evaluated on Incidence of severe ventricular arrhythmia (IRR 1.342, 95% CI 1.096-1.642). Domperidone exposure was associated with a modestly increased risk of severe ventricular arrhythmia compared with non-use (adjusted IRR 1.342), though this risk was lower than that of itopride.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: